UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported)    April 23, 2008

AspenBio Pharma, Inc.

(Exact name of registrant as specified in charter)

          Colorado    
(State or other jurisdiction
       of incorporation)   001-33675   
(Commission
File Number)      84-1553387  
   (IRS Employer
 Identification No.)

1585 South Perry Street, Castle Rock, CO
(Address of principal executive offices)   80104  
(Zip Code)

        Registrant’s telephone number, including area code (303) 794-2000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[   ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[   ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[   ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[   ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01  —  Other Events

        On April 23, 2008, the Registrant issued a press release titled; “AspenBio Pharma Advances AppyScore Towards Clinical Trials with Improved Specificity for Detecting Human Appendicitis”. A copy of this press release is attached hereto as Exhibit 99.1.

Item 9.01  —  Exhibits.

Exhibit
No. Description

99.1 Press release dated April 23, 2008 titled, "AspenBio Pharma Advances AppyScore Towards Clinical Trials with Improved Specificity for Detecting Human Appendicitis"

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                          
                          

Date:   April 23, 2008
                          
                          
                           AspenBio Pharma, Inc.
(Registrant)

/s/ Jeffrey G. McGonegal
Jeffrey G. McGonegal
Chief Financial Officer